TP53 and carcinoma: A significant increase in the DNA methylation levels of the RSPO2 promoter was observed along the progression of the adenoma to carcinoma sequence (Fig. 6C, Additional file 15: Table S11), and this effect was maximized in the context of patients with APC/KRAS/TP53 mutations.